SILVERARC CAPITAL MANAGEMENT, LLC
CIK 1816307
13F filing for Q2 2026・No. 2,650
- Holdings
- US$962.15M
- Quarter change
- −US$17.66M
- Entries
- 73
- Net bought (estimate)
- −US$70.45M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 20
- Sold out 22
- Cut 27
- Added 16
- Corporate actions 0
- Unchanged 2
Largest holdings
65 stocks worth US$898.52M, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| ASCENDIS PHARMA A/SORD SHS | New | 206,234 | US$55.01M | 6.12% |
| CELCUITY INCCOM | Added | 500,996 | US$52.41M | 5.83% |
| COGTCOGENT BIOSCIENCES INCCOM | Cut | 1,280,707 | US$49.56M | 5.52% |
| URGNUROGEN PHARMA LTDCOM | Cut | 1,301,979 | US$47.91M | 5.33% |
| IMMUNOME INCCOM | Added | 2,017,009 | US$42.74M | 4.76% |
| DIANTHUS THERAPEUTICS INCCOM | Cut | 390,000 | US$38.02M | 4.23% |
| RYTMRHYTHM PHARMACEUTICALS INCCOM | Added | 311,461 | US$34.58M | 3.85% |
| ORUKA THERAPEUTICS INCCOM | Added | 352,802 | US$33.58M | 3.74% |
| GLUEMONTE ROSA THERAPEUTICS INCCOM | Cut | 1,108,295 | US$26.82M | 2.98% |
| SYNDAX PHARMACEUTICALS INCCOM | Added | 1,214,390 | US$26.55M | 2.95% |
Sign in (free) to see its 50 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 13, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.